Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.
Jiménez-Cortegana C, Palazón-Carrión N, Martin Garcia-Sancho A, Nogales-Fernandez E, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Rueda Dominguez A, Casanova-Espinosa M, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Labrador J, Salar-Silvestre A, Rodriguez-Abreu D, Galvez-Carvajal L, Provencio M, Sánchez-Beato M, Guirado-Risueño M, Espejo-García P, Lejeune M, Álvaro T, Sánchez-Margalet V, de la Cruz-Merino L; Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA); Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA); Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA). Jiménez-Cortegana C, et al. J Immunother Cancer. 2021 Jun;9(6):e002323. doi: 10.1136/jitc-2020-002323. J Immunother Cancer. 2021. PMID: 34158317 Free PMC article.
New horizons in breast cancer: the promise of immunotherapy.
de la Cruz-Merino L, Palazón-Carrión N, Henao-Carrasco F, Nogales-Fernández E, Álamo-de la Gala M, Vallejo-Benítez A, Chiesa M, Sánchez-Margalet V; GEICAM (Spanish Breast Cancer Research Group) and GÉTICA (Spanish Group for Cancer Immuno-Biotherapy). de la Cruz-Merino L, et al. Clin Transl Oncol. 2019 Feb;21(2):117-125. doi: 10.1007/s12094-018-1907-3. Epub 2018 Jun 18. Clin Transl Oncol. 2019. PMID: 29916188 Free article. Review.
Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer.
Palazón-Carrión N, Jiménez-Cortegana C, Sánchez-León ML, Henao-Carrasco F, Nogales-Fernández E, Chiesa M, Caballero R, Rojo F, Nieto-García MA, Sánchez-Margalet V, de la Cruz-Merino L; Spanish Breast Cancer Group (GEICAM) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA). Palazón-Carrión N, et al. Sci Rep. 2021 Jul 13;11(1):14426. doi: 10.1038/s41598-021-93838-w. Sci Rep. 2021. PMID: 34257359 Free PMC article.
Publisher Correction: Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer.
Palazón-Carrión N, Jiménez-Cortegana C, Sánchez-León ML, Henao-Carrasco F, Nogales-Fernández E, Chiesa M, Caballero R, Rojo F, Nieto-García MA, Sánchez-Margalet V, de la Cruz-Merino L; Spanish Breast Cancer Group (GEICAM) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA). Palazón-Carrión N, et al. Sci Rep. 2021 Aug 30;11(1):17639. doi: 10.1038/s41598-021-96901-8. Sci Rep. 2021. PMID: 34462490 Free PMC article. No abstract available.
Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial.
Jiménez-Cortegana C, Sánchez-Martínez PM, Palazón-Carrión N, Nogales-Fernández E, Henao-Carrasco F, Martín García-Sancho A, Rueda A, Provencio M, de la Cruz-Merino L, Sánchez-Margalet V. Jiménez-Cortegana C, et al. Cancers (Basel). 2021 Sep 15;13(18):4622. doi: 10.3390/cancers13184622. Cancers (Basel). 2021. PMID: 34572849 Free PMC article.
Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study.
de la Cruz-Merino L, Gion M, Cruz-Jurado J, Quiroga V, Andrés R, Moreno F, Alonso-Romero JL, Ramos M, Holgado E, Cortés J, López-Miranda E, Henao-Carrasco F, Palazón-Carrión N, Rodríguez LM, Ceballos I, Casas M, Benito S, Chiesa M, Bezares S, Caballero R, Jiménez-Cortegana C, Sánchez-Margalet V, Rojo F. de la Cruz-Merino L, et al. Among authors: palazon carrion n. Cancers (Basel). 2021 Oct 29;13(21):5432. doi: 10.3390/cancers13215432. Cancers (Basel). 2021. PMID: 34771596 Free PMC article.
Circulating regulatory T cells from breast cancer patients in response to neoadjuvant chemotherapy.
Sánchez-Margalet V, Barco-Sánchez A, Vilariño-García T, Jiménez-Cortegana C, Pérez-Pérez A, Henao-Carrasco F, Virizuela-Echaburu JA, Nogales-Fernández E, Álamo-de la Gala MC, Lobo-Acosta MA, Palazón-Carrión N, Nieto A, de la Cruz-Merino L. Sánchez-Margalet V, et al. Transl Cancer Res. 2019 Feb;8(1):59-65. doi: 10.21037/tcr.2018.12.30. Transl Cancer Res. 2019. PMID: 35116734 Free PMC article.
Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics.
García-Domínguez DJ, Hontecillas-Prieto L, Palazón-Carrión N, Jiménez-Cortegana C, Sánchez-Margalet V, de la Cruz-Merino L. García-Domínguez DJ, et al. Among authors: palazon carrion n. Cancers (Basel). 2022 Mar 13;14(6):1469. doi: 10.3390/cancers14061469. Cancers (Basel). 2022. PMID: 35326620 Free PMC article. Review.
Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases.
Martínez-Chinchilla C, Vazquez-Montero L, Palazón-Carrión N, Fernández-Román IM, López-Barba J, de la Cruz-Merino L, Rodríguez-Baño J, Palacios-Baena ZR. Martínez-Chinchilla C, et al. Among authors: palazon carrion n. Front Immunol. 2022 Apr 14;13:860891. doi: 10.3389/fimmu.2022.860891. eCollection 2022. Front Immunol. 2022. PMID: 35493500 Free PMC article. Clinical Trial.
18 results